Galactose engineered solid lipid nanoparticles for targeted delivery of doxorubicin

Colloids and Surfaces B: Biointerfaces

Volumn 134, Issue , 2015, Pages 47-58

  Jain, Ashay ^a,b   Kesharwani, Prashant ^b,c   Garg, Neeraj K ^a,b   Jain, Atul ^a,b   Jain, Som Akshay ^b   Jain, Amit Kumar ^b   Nirbhavane, Pradip ^a   Ghanghoria, Raksha ^b   Tyagi, Rajeev Kumar ^d,e   Katare, Om Prakash ^a  

^a PANJAB UNIVERSITY   (India)

^b DR H S GOUR UNIVERSITY   (India)

^c WAYNE STATE UNIVERSITY   (United States)

^d AUGUSTA UNIVERSITY   (United States)

^e REGIONAL CENTRE FOR BIOTECHNOLOGY   (India)

Author keywords

Cytotoxicity; Doxorubicin; Galactose; Lectin; Solid lipid nanoparticles; Targeting

Indexed keywords

ANTIGENS; BIOCOMPATIBILITY; CELL MEMBRANES; CONTROLLED DRUG DELIVERY; CYTOTOXICITY; DISEASES; EFFICIENCY; LIPOSOMES; NANOPARTICLES; PARTICLE SIZE; PROTEINS;

DOXORUBICIN; GALACTOSE; LECTIN; SOLID LIPID NANOPARTICLE (SLN); TARGETING;

TARGETED DRUG DELIVERY;

DOXORUBICIN; GALACTOSE; LECTIN RECEPTOR; LIPOSOME; OCTADECYLAMINE; PHOSPHATIDYLCHOLINE; POLYSORBATE 80; SOLID LIPID NANOPARTICLE; ANTINEOPLASTIC ANTIBIOTIC; LIPID; NANOPARTICLE;

A549 CELL LINE; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIOCOMPATIBILITY; CANCER IMMUNOTHERAPY; CELL NUCLEUS; CELL SURFACE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; FEMALE; FINANCIAL MANAGEMENT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RAT; SCALE UP; SUSTAINED RELEASE FORMULATION; ZETA POTENTIAL; ANIMAL; CHEMISTRY; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; FEMALE; GALACTOSE; LIPIDS; MALE; NANOPARTICLES; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 84938385941     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2015.06.027     Document Type: Article

References (58)

1. Jain K., Kesharwani P., Gupta U., Jain N.K. A review of glycosylated carriers for drug delivery. Biomaterials 2012, 33:4166-4186.
2. Bies C., Lehr C.-M., Woodley J.F. Lectin-mediated drug targeting: history and applications. Adv. Drug Deliv. Rev. 2004, 56:425-435.
3. Kesharwani P., Tekade R.K., Jain N.K. Dendrimer generational nomenclature: the need to harmonize. Drug Discov. Today 2015, 20:497-499.
4. Kesharwani P., Jain K., Jain N.K. Dendrimer as nanocarrier for drug delivery. Prog. Polym. Sci. 2014, 39:268-307.
5. Kesharwani P., Tekade R.K., Gajbhiye V., Jain K., Jain N.K. Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison. Nanomed. Nanotechnol. Biol. Med. 2011, 7:295-304.
6. Agarwal A., Saraf S., Asthana A., Gupta U., Gajbhiye V., Jain N.K. Ligand based dendritic systems for tumor targeting. Int. J. Pharm. 2008, 350:3-13.
7. Kelly C., Jefferies C., Cryan S.-A. Targeted liposomal drug delivery to monocytes and macrophages. J. Drug Deliv. 2011, 727241. 10.1155/2011/727241.
8. Takagi H., Numazaki M., Kajiwara T., Abe Y., Ishii M., Kato C., et al. Cooperation of specific ICAM-3 grabbing nonintegrin-related 1 (SIGNR1) and complement receptor type 3 (CR3) in the uptake of oligomannose-coated liposomes by macrophages. Glycobiology 2009, 19:258-266.
9. Kesharwani P., Iyer A.K. Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery. Drug Discov. Today 2015, 20:536-547.
10. Sharma A., Sharma S., Khuller G.K. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J. Antimicrob. Chemother. 2004, 54:761-766.
11. Storm P.B., Moriarity J.L., Tyler B., Burger P.C., Brem H., Weingart J. Polymer delivery of camptothecin against 9L gliosarcoma: release, distribution, and efficacy. J. Neurooncol. 2002, 56:209-217.
12. Moghimi S.M., Hunter A.C., Murray J.C. Nanomedicine: current status and future prospects. FASEB J. 2005, 19:311-330.
13. Kesharwani P., Banerjee S., Padhye S., Sarkar F.H., Iyer A.K. Parenterally administrable nano-micelles of 3,4-difluorobenzylidene curcumin for treating pancreatic cancers. Colloids Surf. B: Biointerfaces 2015, 132:138-145.
14. Vyas S.P., Khar R.K. Targeted and Controlled Drug Delivery Novel Carrier Systems 2002, CBS Publishers, New Delhi. 1st ed.
15. Kesharwani P., Gajbhiye V., Jain N.K. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials 2012, 33:7138-7150.
16. Petri B., Bootz A., Khalansky A., Hekmatara T., Müller R., Uhl R., et al. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J. Control. Release 2007, 117:51-58.
17. Singh R., Kesharwani P., Mehra N.K., Singh S., Banerjee S., Jain N.K. Development and characterization of folate anchored Saquinavir entrapped PLGA nanoparticles for anti-tumor activity. Drug Dev. Ind. Pharm. 2015, 1-14. 10.3109/03639045.2015.1019355.
18. Jain A., Jain K., Kesharwani P., Jain N.K. Low density lipoproteins mediated nanoplatforms for cancer targeting. J. Nanoparticle Res. 2013, 15:1888. 10.1007/s11051-013-1888-7.
19. Kesharwani P., Mishra V., Jain N.K. Generation dependent hemolytic profile of folate engineered poly(propyleneimine) dendrimer. J. Drug Deliv. Sci. Technol. 2015, 28:1-6.
20. Kesharwani P., Tekade R.K., Jain N.K. Generation dependent safety and efficacy of folic acid conjugated dendrimer based anticancer drug formulations. Pharm. Res. 2015, 32:1438-1450.
21. Birdhariya B., Kesharwani P., Jain N.K. Effect of surface capping on targeting potential of folate decorated poly (propylene imine) dendrimers. Drug Dev. Ind. Pharm. 2014, 1-7.
22. Schwarz C., Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery. II. Drug incorporation and physicochemical characterization. J. Microencapsul. 1999, 16:205-213.
23. Miglietta A., Cavalli R., Bocca C., Gabriel L., Rosa Gasco M. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int. J. Pharm. 2000, 210:61-67.
24. Reddy L.H., Sharma R.K., Chuttani K., Mishra A.K., Murthy R.R. Etoposide-incorporated tripalmitin nanoparticles with different surface charge: formulation, characterization, radiolabeling, and biodistribution studies. AAPS J. 2004, 6:e23. 10.1208/aapsj060323.
25. Magenheim B., Levy M.Y., Benita S. A new in vitro technique for the evaluation of drug release profile from colloidal carriers - ultrafiltration technique at low pressure. Int. J. Pharm. 1993, 94:115-123.
26. Agarwal A., Agrawal H., Tiwari S., Jain S., Agrawal G.P. Cationic ligand appended nanoconstructs: a prospective strategy for brain targeting. Int. J. Pharm. 2011, 421:189-201.
27. Brigger I., Morizet J., Laudani L., Aubert G., Appel M., Velasco V., et al. Negative preclinical results with stealth nanospheres-encapsulated doxorubicin in an orthotopic murine brain tumor model. J. Control. Release 2004, 100:29-40.
28. D'Arpa P., Liu L.F. Topoisomerase-targeting antitumor drugs. Biochim. Biophys. Acta 1989, 989:163-177.
29. Tardi P.G., Boman N.L., Cullis P.R. Liposomal doxorubicin. J. Drug Target. 1996, 4:129-140.
30. Agarwal A., Lariya N., Saraogi G., Dubey N., Agrawal H., Agrawal G.P. Nanoparticles as novel carrier for brain delivery: a review. Curr. Pharm. Des. 2009, 15:917-925.
31. Martindale The Extra Pharmacopoeia 1996, 567. Royal Pharmaceutical Society London/Pharmaceutical Press, London, Google Search, n.d. 31st ed.
32. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994, 54:987-992.
33. Schubert M.A., Müller-Goymann C.C. Solvent injection as a new approach for manufacturing lipid nanoparticles-evaluation of the method and process parameters. Eur. J. Pharm. Biopharm. 2003, 55:125-131.
34. Kumar P.V., Asthana A., Dutta T., Jain N.K. Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers. J. Drug Target. 2006, 14:546-556.
35. Green F. The Sigma-Aldrich Handbook of Stains, Dyes, and Indicators 1990, Aldrich Chemical Co., Milwaukee, WI.
36. Reddy L.H., Murthy R.S.R. Pharmacokinetics and biodistribution studies of doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles synthesized by two different techniques. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech. Repub. 2004, 148:161-166.
37. Reddy L.H., Meda N., Murthy R.R. Rapid and sensitive HPLC method for the estimation of doxorubicin in dog blood-the silver nitrate artifact. Acta Pharm. 2005, 55:81-91.
38. Kesharwani P., Tekade R.K., Jain N.K. Formulation development and in vitro-in vivo assessment of the fourth-generation PPI dendrimer as a cancer-targeting vector. Nanomedicine (Lond) 2014, 9:2291-2308.
39. Bhadra D., Bhadra S., Jain S., Jain N.K. A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int. J. Pharm. 2003, 257:111-124.
40. Kolhe P., Misra E., Kannan R.M., Kannan S., Lieh-Lai M. Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers. Int. J. Pharm. 2003, 259:143-160.
41. Pauwels B., Korst A.E.C., de Pooter C.M.J., Pattyn G.G.O., Lambrechts H.A.J., Baay M.F.D., et al. Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies. Cancer Chemother. Pharmacol. 2003, 51:221-226.
42. Agarwal A., Gupta U., Asthana A., Jain N.K. Dextran conjugated dendritic nanoconstructs as potential vectors for anti-cancer agent. Biomaterials 2009, 30:3588-3596.
43. Thomas T.P., Majoros I.J., Kotlyar A., Kukowska-Latallo J.F., Bielinska A., Myc A., et al. Targeting and inhibition of cell growth by an engineered dendritic nanodevice. J. Med. Chem. 2005, 48:3729-3735.
44. Yoo H.S., Park T.G. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. J. Control. Release 2004, 100:247-256.
45. Jain A.K., Jain A., Garg N.K., Jain A., Jain S.A., Tyagi R.K., et al. Adapalene loaded solid lipid nanoparticles gel: an effective approach for acne treatment. Colloids Surf. B: Biointerfaces 2014, 121:222-229.
46. Kharya P., Jain A., Gulbake A., Shilpi S., Jain A., Hurkat P., et al. Phenylalanine-coupled solid lipid nanoparticles for brain tumor targeting. J. Nanoparticle Res. 2013, 15:2022. 10.1007/s11051-013-2022-6.
47. Dalwadi G., Sunderland B. An ion pairing approach to increase the loading of hydrophilic and lipophilic drugs into PEGylated PLGA nanoparticles. Eur. J. Pharm. Biopharm. 2009, 71:231-242.
48. Xu F., Yan T.-T., Luo Y.-L. Synthesis and micellization of thermosensitive PNIPAAm-b-PLA amphiphilic block copolymers based on a bifunctional initiator. Macromol. Res. 2011, 19:1287-1295.
49. Wei H., Wu D.-Q., Li Q., Chang C., Zhou J.-P., Zhang X.-Z., et al. Preparation of shell cross-linked thermoresponsive micelles as well as hollow spheres based on P(NIPAAm-co-HMAAm-co-MPMA)-b-PCL. J. Phys. Chem. C 2008, 112:15329-15334.
50. Jain S.K., Gupta Y., Jain A., Saxena A.R., Khare P., Jain A. Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery. Nanomedicine 2008, 4:41-48.
51. Jain A., Agarwal A., Majumder S., Lariya N., Khaya A., Agrawal H., et al. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J. Control. Release 2010, 148:359-367.
52. Müller R.H., Rühl D., Runge S., Schulze-Forster K., Mehnert W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm. Res. 1997, 14:458-462.
53. Müller R.H., Maassen S., Weyhers H., Mehnert W. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J. Drug Target. 1996, 4:161-170.
54. Moore A., Basilion J.P., Chiocca E.A., Weissleder R. Measuring transferrin receptor gene expression by NMR imaging. Biochim. Biophys. Acta 1998, 1402:239-249.
55. Budzynska R., Nevozhay D., Kanska U., Jagiello M., Opolski A., Wietrzyk J., et al. Antitumor activity of mannan-methotrexate conjugate in vitro and in vivo. Oncol. Res. 2007, 16:415-421.
56. Schoepf U., Marecos E.M., Melder R.J., Jain R.K., Weissleder R. Intracellular magnetic labeling of lymphocytes for in vivo trafficking studies. Biotechniques 1998, 24:642-646. 648-651.
57. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46:6387-6392.
58. Venne A., Li S., Mandeville R., Kabanov A., Alakhov V. Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res. 1996, 56:3626-3629.